AMEX · NSRX
Nasus Pharma Ltd.
Healthcare · Biotechnology
$3.85
Down-$0.01 (-0.26%)
Updated Oct 6, 2026, 11:58 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.89M
- P/E ratio
- -38.44
- Dividend yield
- 0.00%
- 52-week range
- $1.98 – $5.20
- Volume
- 9.57K
- Avg. volume
- 13.21K
Price performance · NSRX
NSRX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
NSRX closed at $3.85 after 20 trading sessions, down 0.77% for the selected period.
- Last close
- $3.85
- Period change
- -0.77%
- Period low
- $3.35
- Period high
- $3.92
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.00 | $4.03 | $3.80 | $3.85 | 9.57K |
| Oct 2, 2026 | $3.82 | $4.10 | $3.79 | $3.92 | 28.71K |
| Oct 1, 2026 | $4.00 | $4.0074 | $3.76 | $3.815 | 28.62K |
| Sep 30, 2026 | $4.00 | $4.00 | $3.60 | $3.69 | 57.38K |
| Sep 29, 2026 | $3.76 | $3.79 | $3.5382 | $3.57 | 37.36K |
| Sep 28, 2026 | $3.69 | $3.78 | $3.35 | $3.59 | 115.67K |
| Sep 25, 2026 | $3.4999 | $3.595 | $3.425 | $3.48 | 20.96K |
| Sep 24, 2026 | $3.35 | $3.50 | $3.35 | $3.48 | 3.94K |
| Sep 23, 2026 | $3.57 | $3.79 | $3.50 | $3.64 | 14.92K |
| Sep 22, 2026 | $3.48 | $3.68 | $3.45 | $3.57 | 12.45K |
| Sep 21, 2026 | $3.46 | $3.53 | $3.35 | $3.44 | 6.43K |
| Sep 18, 2026 | $3.35 | $3.58 | $3.35 | $3.53 | 12.02K |
| Sep 17, 2026 | $3.535 | $3.5857 | $3.46 | $3.53 | 7.64K |
| Sep 16, 2026 | $3.64 | $3.72 | $3.41 | $3.46 | 10.95K |
| Sep 15, 2026 | $3.62 | $3.7665 | $3.45 | $3.59 | 18.44K |
| Sep 14, 2026 | $3.2623 | $3.80 | $3.2623 | $3.65 | 21.17K |
| Sep 11, 2026 | $3.4984 | $3.50 | $3.4049 | $3.4049 | 4.21K |
| Sep 10, 2026 | $3.16 | $3.4769 | $3.16 | $3.35 | 10.72K |
| Sep 9, 2026 | $3.47 | $3.565 | $3.17 | $3.55 | 4.44K |
| Sep 8, 2026 | $3.53 | $3.9731 | $3.47 | $3.88 | 8.68K |
Latest NSRX news
The latest Smart Investors Daily articles mentioning NSRX.
Stock researchMarket Activity · Options
Company
Market Activity
Research & News

